



Translation

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Alfresa Holdings Corporation
September 16, 2026

Notice Regarding the Strengthening of Strategy Promotion Systems in the Ethical Pharmaceuticals Wholesaling Business

Plans have been announced to expand the scope of the functions of the Pharmaceutical Sales Strategy Committee*¹ at Alfresa Corporation (head office: Chiyoda-ku, Tokyo; representative director & president: Yusuke Fukujin; hereinafter “Alfresa”), a subsidiary of Alfresa Holdings Corporation. These functions will extend beyond just sales strategies to encompass all areas of the Ethical Pharmaceuticals Wholesaling Business, including strategies concerning logistics and solutions. Said move intends to strengthen the strategy promotion functions of this business. At the same time, steps will be taken to enhance collaboration and coordination on important Groupwide issues. To reflect the newly broadened scope of its functions, the name of the Pharmaceutical Sales Strategy Committee will be changed to the Wholesaling Business Strategy Committee effective October 1, 2026. The details are as follows.

1. Background and Purpose of Strengthening Strategy Promotion Systems

On April 1, 2025, the Alfresa Group established the Pharmaceutical Sales Strategy Committee with the goal of enhancing intra-Group coordination in its core Ethical Pharmaceuticals Wholesaling Business. This committee has since been contributing to the sharing of sales strategies and to increased coordination among Group companies.

In the time since, the operating environment surrounding the Ethical Pharmaceuticals Wholesaling Business has changed, increasing the need for Groupwide efforts to improve distribution efficiency, provide solutions in response to customer needs, and optimize business operational platforms.

Based on this recognition, the decision was made to expand the scope of the Pharmaceutical Sales Strategy Committee’s functions to include the entirety of the Ethical Pharmaceuticals Wholesaling Business. This course of action will facilitate Groupwide discussions on logistics strategies and solutions strategies, in addition to sales strategies, and promote the integrated advancement of initiatives in various

fields, while important Groupwide issues will be more-effectively addressed through the enhancement of collaboration and coordination. In conjunction with these efforts, the name of the Pharmaceutical Sales Strategy Committee will be changed to the Wholesaling Business Strategy Committee effective October 1, 2026 in an attempt to more accurately convey the newly broadened scope of its functions and role.

Going forward, the committee will compile shared Groupwide policies, based on which it will promote measures through coordination among Group companies in order to heighten the effectiveness of measures and enhance the Group's ability to address shared issues. The committee will also help accelerate initiatives to achieve the goals of the Alfresa Group's Medium- to Long-Term Vision^{*2} as we seek to make greater contributions to the health of local communities and the prosperity of our customers and business partners.

^{*1} Reference: Notice Regarding the Establishment of the Pharmaceutical Sales Strategy Committee in Alfresa Corporation (published on February 26, 2025, on the Alfresa Holdings Corporation corporate website)

https://ssl4.eir-parts.net/doc/2784/ir_material17/245779/00.pdf

^{*2} Reference: Notice regarding the Formulation of the Alfresa Group's Medium- to Long-Term Vision (published on May 15, 2023, on the Alfresa Holdings Corporation corporate website)

https://www.alfresa.com/eng/ir/pdf/mediumtolong_termvision.pdf

2. Overview of the Wholesaling Business Strategy Committee

(1) Positioning

The Wholesaling Business Strategy Committee will be positioned as a venue for discussing important issues pertaining to the Ethical Pharmaceuticals Wholesaling Business centered on Alfresa so as to compile shared Groupwide policies and for sharing understanding regarding said issues.

Based on the policies compiled by the Wholesaling Business Strategy Committee, measures will be promoted through coordination among Group companies in order to boost the competitiveness of the Ethical Pharmaceuticals Wholesaling Business in pursuit of ongoing growth and improved corporate value.

(2) Major Areas of Responsibility

- i. Sales strategies for the Ethical Pharmaceuticals Wholesaling Business
- ii. Logistics strategies for the Ethical Pharmaceuticals Wholesaling Business
- iii. Solutions strategies for the Ethical Pharmaceuticals Wholesaling Business
- iv. Important issues requiring Groupwide responses
- v. Other areas related to accomplishing the goals of the Wholesaling Business Strategy Committee

(3) Membership of the Committee

Chair	Yusuke Fukujin, Representative Director & President, Alfresa Corporation, Representative Director & Executive Vice President, Ethical Pharmaceuticals Wholesaling Business, International Business, Alfresa Holdings Corporation
Vice Chairs	Yosuke Kiyoshita, Representative Director & President, Shikoku Alfresa Corporation Takuji Takahashi, Representative Director & President, TS Alfresa Corporation Hiromitsu Kawajiri, Representative Director & President, Meisho Co., Ltd. Katsuya Higa, Representative Director & President, RYUYAKU CO., LTD. Yasushi Kobayashi, Representative Director & President, Tohoku Alfresa Corporation Makoto Sakakibara, Representative Director & President, Miyazaki Onsendo Shoten Co., Ltd.
Assistant Chair	Yoshihisa Yamada, Director, Vice President & Executive Officer, General Manager of Medical Sales Division, Alfresa Corporation
Members	Hironori Miyake, Executive Officer, General Manager of Kitakanto & Ko-Shin-Etsu Regional Office, Medical Sales Division, Alfresa Corporation Kazuhito Matsui, Vice President & Executive Officer, General Manager of Tokyo Regional Office, Medical Sales Division, Alfresa Corporation Hideyoshi Osaku, Executive Officer, General Manager of Shutoken Regional Office, Medical Sales Division, Alfresa Corporation Kenji Makino, Executive Officer, General Manager of Tokai Regional Office, Medical Sales Division, Alfresa Corporation Masaki Yoshioka, Executive Officer, General Manager of Kansai Regional Office, Medical Sales Division, Alfresa Corporation Shigeo Izumi, Officer, General Manager of Kyushu Regional Office, Medical Sales Division, Alfresa Corporation Akira Akazawa, Executive Officer, General Manager of National Corporate Accounts Division, Alfresa Corporation Daisuke Miyauchi, Executive Officer, General Manager of Sales Division, Shikoku Alfresa Corporation Kazuhiko Kakimura, Director and Senior Executive Officer, Chief Sales Officer, TS Alfresa Corporation Kanji Orimoto, Director and Executive Officer, General Manager of Business Design Unit, Meisho Co., Ltd. Tatsuya Kinjo, Director and Executive Officer, General Manager of Sales Division, RYUYAKU CO., LTD.

	Yoshinori Kikuchi, General Manager of Sales Division, Tohoku Alfresa Corporation Akiyoshi Kakihara, Director, General Manager of Sales Division, Miyazaki Onsendo Shoten Co., Ltd.
Advisors	Ryuji Arakawa, Representative Director & Chairman, Alfresa Corporation, Representative Director & President, Alfresa Holdings Corporation Shigeki Ohashi, Director, Vice President & Executive Officer, Group Business Strategy, Alfresa Holdings Corporation

Notes:

1. Positions are as of October 1, 2026.
2. The Wholesaling Business Strategy Committee will have representatives of sales functions from Group companies as its core members, and individuals overseeing other areas at affiliates or other relevant organizations may participate in meetings to take part in discussions on logistics strategies, solutions strategies, or other specialized topics. In this manner, the committee will incorporate specialized insight pertaining to the relevant areas as it compiles Groupwide policies and uses this insight to guide measures at Group companies.

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to realizing its mission, “we create and deliver a fresh life for all,” through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, operating dispensing pharmacies, regenerative medicine-related business, and CRO business. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥3.1 trillion for the fiscal year ended March 31, 2026. For more information, please see: <https://www.alfresa.com/eng/>